Press Room

Webinar - AMLM: the perks of method performance verification in pharmaceutical quality framework

Start
Thursday, October 22, 2020 - 16:00
End
Thursday, October 22, 2020 - 16:00
Location: online

Thursday, October 22nd, 2020 | 12 PM (EDT), 4 PM (BST), 5 PM (CEST)

 

Watch On-Demand Webinar

 

Speakers

Lúcia Volta e Sousa - Analytical Chemist, R&D Analytical Development
Nuno Matos - Director, Quality System Management

 

Analytical Method Lifecycle Management (AMLM) principles require a holistic perspective where method robustness is considered together with process and product variability. AMLM views all method related activities as a continuum and interrelated multi-step process, where knowledge and risk management are the key enablers.

This includes three stages, Method design (Stage 1), qualification (Stage 2) and Performance Verification (Stage 3). All knowledge gathered in Stage 1 and 2 allow an effective definition of the Analytical Control Strategy (ACS), that provides directly the performance parameters that can be continuously monitored on Stage 3. In contrast to the first two stages, Stage 3 offers the possibility of an enhanced data set to collect, analyze and evaluate method performance. This promotes a continuous method evaluation, ensuring it remains fit for the intended purpose or, if not, supports the corrective actions required for method improvement. Moreover, this monitoring program should be aligned with the Quality Management System (QMS) in place, since it includes an efficient change control and deviation management system.

With this webinar an overview of AMLM Stage 3 will be presented, including its implications, advantages and case studies, and its capturing within the current QMS. Additionally, regulatory and industry initiatives that mark the evolution of these concepts and capture the current and future expectation of pharmaceutical framework will be highlighted.

 

In this webinar you’ll learn:

  • Analytical Method Lifecycle Management

  • Method Performance verification program

  • ICH Q14 and Q12

  • USP

 

Watch On-Demand Webinar

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025